WWW.NET.KNIGI-X.RU
    -
 

Pages:     | 1 |   ...   | 3 | 4 ||

- . ...

-- [ 5 ] --

Fabian et al. // J Thorac Oncol. - 2013. - Vol. 14, N 11. - P. 62876292.

503. Tao, H. Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller. / H. Tao, T. Hayashi, F. Sano et al. // J Surg Res. - 1993. Vol. 2, N 6. - P. 341347.

504. Tateishi, M. The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung. / M. Tateishi, S. Kaneko, Y. Fukuyama et al. // Eur J Surg Oncol. - 2000. - Vol. 20, N 1. - P. 505510.

505. Thibault, C. HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review. / C. Thibault, W. Khodari, M. Lequoy et al. // Crit Rev Oncol Hematol. - 2009. - Vol. 17, N 5. - P. 390395.

506. Tiseo, M. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. / M. Tiseo, G.

Rossi, M. Capelletti et al. // Lung Cancer. - 2003. - Vol. 56, N 4. - P. 198204.

507. Toh, C.K. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. / C.K. Toh, B. Ahmad, R. Soong et al. // J Thorac Oncol. - 2002. - Vol. 296, N 5574. - P. 18831886.

508. Tomashefski, J.F. Dail and Hammar's Pulmonary Pathology Volume II: Neoplastic Lung Disease. / J.F. Tomashefski. - New York: Springer, 2008 - 869 .



509. Tomita, M. Prognostic significance of bcl-2 expression in resected pN2 nonsmall cell lung cancer. / M. Tomita, Y. Matsuzaki, M. Edagawa et al. // EJSO. - 2012. Vol. 13, N 12. - P. 63116318.

510. Tomobe, M. Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor. / M. Tomobe, T. Shimazui, K. Uchida et al. // J Urol. - 2008. - Vol. 23, N 8. - P. 987993.

511. Torre, W. Postoperative complications of lung resection after induction chemotherapy using Paclitaxel (and radiotherapy) for advanced non-small lung cancer. / W. Torre, A. Sierra // J Cardiovasc Surg (Torino). - 2007. - Vol. 22, N 2. - P. 318325.

512. Travis, W.D. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. / W.D. Travis, E.

Brambilla, H.K. Muller-Hermelink, C.C. Harris. - IARC Press: Lyon, 2004. - 9-124 .

513. Trere, D. AgNOR staining and quantification. / D. Trere // Micron. - 2013. Vol. 21, N 6. - P. 693699.

514. Trer, D. Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients. / D. Trer, C. Ceccarelli, M.

Migaldi et al. // Appl Immunohistochem Mol Morphol. - 2006. - Vol. 12, N 24. - P.

72157220.

515. Trer, D. Quantitative analysis of AgNOR proteins: a reliable marker of the rapidity of cell duplication and a significant prognostic parameter in tumour pathology. / D. Trer // Adv Clin Path. - 2012. - Vol. 25, Suppl 1. - P. 1117.

516. Trivella, M. Microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of individual patient data. / M. Trivella, F. Pezzella, U. Pastorino et al. // Lancet Oncol. - 2001. - Vol. 44, N 3. - P. 180 188.

517. Tsoukalas, N. The clinical and pathological significance of RCAS1 expression as a prognostic biomarker in non-small cell lung cancer. / N. Tsoukalas, I.D. Kostakis, S.





Siakavellas et al. // In Vivo. - 2005. - Vol. 113, N 1. - P. 101108.

518. Tsubochi, H. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. / H. Tsubochi, N. Sato, M. Hiyama et al. // Ann Thorac Surg. - 2012. - Vol. 29, N 4. - P. 25862593.

519. Tsutani, Y. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. / Y. Tsutani, Y. Miyata, T. Mimae et al. // J Thorac Cardiovasc Surg. - 2000. - Vol. 31, N 2. - P. 133141.

520. Tsutsumida, H. MUC4 expression correlates with poor prognosis in smallsized lung adenocarcinoma. / H. Tsutsumida, M. Goto, S. Kitajima et al. // Lung Cancer.

- 1997. - Vol. 182, N 4. - P. 450456.

521. Ulukus, E.C. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. / E.C. Ulukus, H.A. Kargi, B. Sis et al. // Appl Immunohistochem Mol Morphol. - 2002. - Vol. 8, N 3. - P. 734744.

522. Ushijima, C. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. / C. Ushijima, S. Tsukamoto, K.

Yamazaki et al. // Lung Cancer. - 1986. - Vol. 18, N 1. - P. 514.

523. van de Rijn, M. Applications of microarrays to histopathology. / M. van de Rijn, C.B. Gilks // Histopathology. - 1995. - Vol. 33, N 2. - P. 8388.

524. Van der Auwera, I. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. / I. Van der Auwera, Y. Cao, J.C.

Tille et al. // Br J Cancer. - 2003. - Vol. 123, N 6. - P. 18581867.

525. Varella-Garcia, M. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. / M. Varella-Garcia, T. Mitsudomi, Y. Yatabe et al. // J Thorac Oncol. - 2006. - Vol. 20, N 5. - P. 599604.

526. Varlotto, J.M. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. / J.M. Varlotto, A. Recht, M. Nikolov et al. // Cancer. - 2002.

- Vol. 8, N 3. - P. 222233.

527. Walczak, H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. / H. Walczak, P.H. Krammer // Exp Cell Res. - 2012. - Vol. 3, N 4. - P. 636640.

528. Walker, C. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. / C. Walker, L. Robertson, M.W. Myskow, G.R.

Dixon // Br J Cancer. - 2012. - Vol. 65, N 5. - P. 210215.

529. Walker, C. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. / C. Walker, L.J. Robertson, M.W. Myskow et al. // Br J Cancer. Vol. 7, N 3. - P. 205211.

530. Wang, J. Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature. / J. Wang, K. Li, B. Wang, J. Bi // Mol Biol Rep. - 2002. - Vol. 9, N 2. - P. 423432.

531. Wang, J. Prognostic significance of circulating tumor cells in non-small cell lung cancer patients: a meta-analysis. / J. Wang, K. Wang, J. Xu et al. // PLoS One. Vol. 40, N 3. - P. 422430.

532. Wang, S. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. / S. Wang, M. Hossein Saboorian, E.P. Frenkel et al. // Mod Pathol. - 2002. - Vol. 9, N 1. - P. 13.

533. Wang, Y. Clinical and prognostic significance of podoplanin-positive lymphatic vessel density in non-small cell lung carcinoma. / Y. Wang, J.G. Sun, M.F. Ye, Z.T.

Chen // Zhonghua Jie He He Hu Xi Za Zhi. - 2002. - Vol. 93, N 9. - P. 10071011.

534. Wang, Y. Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer. / Y. Wang, X.R. Zhang, J. Fu et al. // Zhonghua Zhong Liu Za Zhi. - 2013. - Vol. 99, N 6. - P. 661666.

535. Warth, A. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. / A. Warth, J. Cortis, A. Soltermann et al. // Br J Cancer. - 2014. - Vol. 97, N 3. - P. 987992.

536. Weber, S.K. Detection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancer. / S.K. Weber, A. Sauerwald, M. Plcher et al.

// Int J Gynecol Cancer. - 2005. - Vol. 11, N 20. - P. 73447353.

537. Wei, M.C. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. / M.C. Wei, W.X. Zong, E.H. Cheng et al. // Science. - 2002. Vol. 38, N 2. - P. 169176.

538. Wei, S. Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification?. / S. Wei, H. Asamura, R. Kawachi et al. // J Thorac Oncol. - 2006. - Vol. 81, N 6. - P. 19881995.

539. Werynska, B. Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. / B.

Werynska, B. Pula, B. Muszczynska-Bernhard et al. // Anticancer Res. - 1997. - Vol. 11.

- P. 440444.

540. Whitson, B.A. Survival after lobectomy versus segmentectomy for stage I nonsmall cell lung cancer: a population-based analysis. / B.A. Whitson, S.S. Groth, R.S. Andrade et al. // Ann Thorac Surg. - 2003. - Vol. 92, N 10. - P. 10981106.

541. Whitson, B.A. T1/T2 non-small-cell lung cancer treated by lobectomy: does tumor anatomic location matter?. / B.A. Whitson, S.S. Groth, R.S. Andrade et al. // J Surg Res. - 2014. - Vol. 70, N 5. - P. 269278.

542. Woenckhaus, M. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. / M. Woenckhaus, J. Merk, R. Stoehr et al. // Hum Pathol. Epub ahead of print].

543. Woo, T. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. / T. Woo, K. Okudela, T. Yazawa et al. // Lung Cancer. - 1997. Vol. 27, N 5. - P. 298304.

544. Woolhouse, I. Variation in lung cancer outcomes in the UK and Europe. / I.

Woolhouse // Clin Med. - 2008. - Vol. 27, N 2. - P. 8390.

545. Wu, S. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. / S. Wu, L. Yu, D. Wang et al. // BMC Cancer. Epub].

546. Xia, Q. Expression and association of HER2 with prognosis in early-stage (T1T2N0M0) non-small cell lung cancer. / Q. Xia, Z. Zhu, J. Wang et al. // Tumour Biol. Vol. 319, N 1. - P. 111.

547. Xu, J.M. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. / J.M. Xu, Y. Han, H.Q. Duan et al. // J Cancer Res Clin Oncol. - 2009. - Vol. 4, N 5. - P.

568577.

548. Xu, Y.J. Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small cell lung cancer: a retrospective analysis. / Y.J. Xu, Y.F. Shao, X. Zhao et al. // J Cancer Res Clin Oncol. - 2007. - Vol. 2, N 7. - P.

603612.

549. Yamaguchi, S. Relationship between the Responses to Simultaneous Double Staining for Ki-67 and AgNOR and the Clinicopathological Features of Non-Small Cell Pulmonary Carcinoma. / S. Yamaguchi // Acta Med Nagasaki. - 2014. - Vol. 35, N 7. - P.

71557162.

550. Yamashita, S. Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer. / S. Yamashita, T. Moroga, K. Tokuishi et al. // Ann Thorac Cardiovasc Surg. Vol. 74. - P. 248252.

551. Yan, S. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. / S. Yan, J. ShunChang, C. Li et al. // BMC Cancer. - 2004. - Vol. 17, N 10. - P. 12351242.

552. Yang, J. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. / J. Yang, N. Ramnath, K.B. Moysich et al. // BMC Cancer. - 2004. Vol. 23, N 4. - P. 347353.

553. Yang, M. The number of resected lymph nodes (nLNs) combined with tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung cancer. / M. Yang, H. Cao, X. Guo et al. // PLoS One. - 2013. - Vol. 143, N 6. - P. 1618 1625.

554. Yano, T. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. / T. Yano, T. Doi, A. Ohtsu et al. // Oncology Reports. - 2014. - Vol. 84, N 2. - P. 182189.

555. Yano, T. Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in nonsmall cell lung cancer-special reference to tumor size. / T. Yano, Y. Morodomi, K. Ito et al. // J Thorac Oncol. - 2010. - Vol. 38, N 5. - P. 628636.

556. Yarden, Y. Untangling the ErbB signalling network. / Y. Yarden, M.X. Sliwkowski // Nat Rev Mol Cell Biol. - 2012. - Vol. 295, N 2. - P. 208214.

557. Yaren, A. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. / A. Yaren, I. Oztop, A. Kargi et al. // Int J Clin Pract. - 2003. Vol. 22, N 14. - P. 35463556.

558. Yasunaga, Y. Prognostic factors of renal cell carcinoma: a multivariate analysis. / Y. Yasunaga, M. Shin, T. Miki et al. // J Surg Oncol. - 2000. - Vol. 20, N 3. - P.

20912096.

559. Yoo, J. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. / J. Yoo, J.H. Jung, M.A. Lee et al. // J Korean Med Sci. - 2010. - Vol. 136, N 7. - P. 10291037.

560. Yoshida, Y. Validation of 7th TNM staging system for lung cancer, based on surgical outcomes. / Y. Yoshida, T. Murayama, Y. Sato et al. // Asian Cardiovasc Thorac Ann. - 2000. - Vol. 182, N 3. - P. 311322.

561. Yousem, S.A. Role of molecular studies in the diagnosis of lung adenocarcinoma. / S.A. Yousem // Modern Pathology. - 2005. - Vol. 24, N 7. - P. 865869.

562. Zaczek, M. Silver-binding nucleolar organizer regions (AgNORs) in bronchial tumors. / M. Zaczek, Z. Chap, W. Szot et al. // Folia Histochem Cytobiol. - 2004. - Vol.

45, N 2. - P. 181188.

563. Zhang, B.C. Peritumoral lymphatic microvessel density is related to poor prognosis in lung adenocarcinoma: A retrospective study of 65 cases. / B.C. Zhang, S.

Guan, Y.F. Zhang et al. // Exp Ther Med. - 2014. - Vol. 26, N 4. - P. 391398.

564. Zhao, H. DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. / H. Zhao, H. Yu, Y. Liu et al. // Clin Neuropathol. - 2004. - Vol. 24, N 3. - P. 19251928.

565. Zhong, X. Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis. / X. Zhong, X. Guan, Q. Dong et al. // Tumour Biol. - 2012. - Vol.

7, N 8. - P. 12631270.

566. Zhu, W.Y. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer. / W.Y. Zhu, Y.Y. Hunag, X.G. Liu et al. // Anat Rec (Hoboken). - 2001. - Vol. 85, N 11. - P. 1706 1712.

567. Zhu, Z.H. Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances. / Z.H. Zhu, T.H. Rong, C.G. Zeng et al. // Ai Zheng. - 2012. - Vol. 62, N 1. - P. 1029.



Pages:     | 1 |   ...   | 3 | 4 ||
:

1 ...

, 12- ...

. 1, . 2 ( 1 , , , 2 , , ayush_ch21@yahoo.com) , , ...

"- - " . 77-27659 26 2007 6 (1/2008) -...

. Semi-RAPD . 619:616.9-636.1 .., . ., .., .., ...

Ͳ [577.23+615.95]574.64 .. . . . , 2, , 46027, - - ...

576.89 (470.323) () 2013 . . 1, . . 2, . . 3, . . 4, . . 5, . . 6, . . 7 ,...

" .....

in vitro 03.03.04 , , ...

"- .. " ...








 
<<     |    
2017 www.net.knigi-x.ru - -

, .
, , , , 1-2 .